Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
About Artivion, Inc.
Artivion, Inc. is a specialized medical device company at the forefront of addressing complex challenges in the treatment of aortic disease through innovative products tailored for cardiac surgery and vascular surgery. Headquartered in suburban Atlanta, Georgia, the company designs, develops, and markets a comprehensive suite of solutions that include advanced mechanical heart valves, aortic stent grafts, surgical sealants, and implantable cardiac and vascular human tissues. Artivion’s product portfolio is purposefully built to support cardiac and vascular surgeons in performing intricate procedures, delivering focused solutions that streamline surgical processes while optimizing patient outcomes.
Core Business Areas and Product Portfolio
Artivion’s product offerings are constructed around four major groups:
- Aortic and Mitral Heart Valves: Engineered to provide reliable and durable performance, these valves are designed to address the challenges of aortic and mitral valve replacements and repairs.
- Aortic Stent Grafts: These devices facilitate minimally invasive repairs for aortic arch diseases, reducing the need for complex open-chest surgeries and simplifying treatment protocols for aneurysms and dissections.
- Surgical Sealants and Adhesives: Developed to complement traditional surgical techniques, these products help control bleeding and support soft tissue repair, ensuring more secure post-operative outcomes.
- Implantable Human Tissues: Artivion also markets processed cardiac and vascular tissues that are used in complex surgeries, enhancing the anatomical and physiological compatibility for critical procedures.
Each of these groups benefits from robust clinical validations and regulatory approvals across multiple international markets, underscoring the company’s commitment to safe and effective medical interventions.
Clinical Evidence and Industry Impact
Artivion distinguishes itself from competitors with strong clinical data derived from rigorous studies, such as the PERSEVERE trial and supporting post-market studies. These studies demonstrate the safety, efficacy, and long-term benefits of its aortic solutions, including improvements in patient outcomes and surgical simplification during complex procedures. The company’s focus on evidence-based technology not only reinforces the credibility of its products but also positions it strategically in a competitive landscape where clinical performance is paramount.
Market Position and Global Outreach
Operating in over 100 countries, Artivion maintains a significant footprint in the global medical device market. By leveraging advanced manufacturing techniques and maintaining high standards in quality and compliance, the company meets the diverse needs of international healthcare providers. Its targeted approach in addressing aortic pathologies—coupled with strategic collaborations and partnership agreements—ensures that Artivion remains a trusted resource for cardiothoracic surgeons worldwide.
Commitment to Innovation and Quality
At the core of Artivion’s strategy is a commitment to delivering simple, elegant solutions that overcome complex surgical challenges. Through continuous research and development, the company not only refines its existing product lines but also explores new technological frontiers in cardiac and vascular surgery. The integration of clinical insights with advanced engineering reinforces its ability to serve a critical segment of healthcare, providing clinicians with tools that enhance precision, safety, and overall patient care.
Investor and Industry Insights
The comprehensive approach adopted by Artivion—from R&D innovation to global distribution and post-market clinical validation—makes it a company of focus for investors and industry analysts alike. Detailed trial data, robust product performance, and strategic market penetration collectively underpin the company’s established role in treating aortic diseases. Artivion’s neutral and fact-based communication of clinical results and market strategies demonstrates its dedication to enhancing outcomes for patients while supporting surgeons in resolving some of the most challenging aspects of cardiac and vascular procedures.
Conclusion
Artivion, Inc. stands as an influential player in the global medical device industry with its specialized focus on aortic disease. Through a well-rounded portfolio of advanced surgical devices and continuous innovation, the company addresses critical gaps in cardiac and vascular treatment. Its evidence-backed products and strategic market presence offer a transparent and comprehensive view of its operations, making it a relevant topic for investors and healthcare professionals seeking an informed understanding of its business model and market impact.
Artivion, Inc. (NYSE: AORT) reported its fourth quarter and full-year 2022 results. The fourth quarter revenues were $79.4 million, flat year-over-year, but up 5% on a non-GAAP constant currency basis. For the full year, revenues reached $313.8 million, a 5% increase on a GAAP basis. Net income for Q4 2022 was $2.2 million compared to a net loss of $20.1 million in Q4 2021. The company anticipates 2023 revenue growth of 8.0% to 12%, with projected revenues between $331 million and $343 million. A CE mark for BioGlue was received, and confidence was noted for PMA approval for PerClot.
Artivion, Inc. (NYSE: AORT) announced its fourth-quarter and full-year 2022 financial results will be released on February 16, 2023, post-market. The Company will host a teleconference at 4:30 p.m. ET to discuss these results, followed by a Q&A session led by Pat Mackin, Chairman and CEO. Interested parties can listen live by dialing 201-689-8261 or access the webcast through the Artivion website. A replay will be available shortly after the call. Artivion specializes in medical devices for aortic diseases, offering products in over 100 countries.
Artivion, Inc. (NYSE: AORT) announced participation in two investor conferences on November 16 and November 17, 2022. The management team will present at the Stifel 2022 Healthcare Conference on November 16 at 9:10 a.m. ET, with a live webcast available on their website. Additionally, they will hold one-on-one meetings at the Canaccord Genuity MedTech Forum on November 17. Artivion specializes in medical devices for aortic diseases and operates in over 100 countries.
Artivion, Inc. (NYSE: AORT) reported third-quarter 2022 revenue of $76.8 million, marking a 6% increase on a GAAP basis compared to Q3 2021. Non-GAAP constant currency revenue grew by 11%. Notable growth came from On-X, with a 17% GAAP and 19% non-GAAP increase. Internationally, revenue rose by 25% in Asia Pacific and 22% in Latin America. However, the company faced a net loss of $13.7 million compared to a profit in the prior year. The revenue outlook for 2022 has been narrowed to $313.0-$316.0 million, projecting 9%-10% growth. The company also anticipates FDA approvals for key products by year-end.
Artivion, Inc. (NYSE: AORT) has announced that its third quarter 2022 financial results will be released on November 3, 2022, after market close. A teleconference will follow at 4:30 p.m. ET to discuss the results, led by Pat Mackin, the company's CEO. Investors can access the live webcast and replay on Artivion's website.
The company specializes in cardiac and vascular solutions for aortic diseases and sells products in over 100 countries worldwide.
Artivion, Inc. (NYSE: AORT) announced the appointment of Elizabeth A. Hoff to its Board of Directors, effective October 1, 2022. Hoff brings over 30 years of experience in the medical device industry, including senior roles in the aortic space. Her expertise will support Artivion's strategic growth initiatives and strengthen its market position in treating aortic diseases. Chairman and CEO Pat Mackin expressed enthusiasm for Hoff's inclusion, expecting her leadership to drive innovation and progress within the company.
Artivion, Inc. (AORT) announced the termination of the PROACT Xa clinical trial on September 23, 2022. The independent Data and Safety Monitoring Board recommended stopping the trial due to insufficient evidence supporting the non-inferiority of apixaban compared to warfarin for patients with On-X mechanical aortic valves. The trial, which began in April 2020, showed a higher incidence of blood clots and stroke in apixaban patients. Despite this setback, Artivion reiterated its commitment to double-digit growth and plans to redirect the previously allocated $10 million funding towards enhancing EBITDA and cash flow.
Artivion, Inc. (NYSE: AORT), a prominent company in cardiac and vascular surgery focused on aortic disease, announced it will present at the Deutsche Bank 30th Annual Leveraged Finance Conference on September 21, 2022, at 9:20 a.m. MST. The presentation will be available via a live webcast on the company's website, with an archived version accessible for 90 days. Artivion specializes in developing solutions for aortic diseases, marketing products in over 100 countries. For further details, visit www.artivion.com.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery, announced its participation in two investor conferences. The first is the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, where a live webcast of the presentation will start at 4:05 p.m. ET. The second is the Lake Street 6th Annual Best Ideas Growth Conference on September 14, 2022, with no webcast available. Artivion focuses on developing solutions for aortic diseases and offers products like aortic stent grafts and On-X mechanical heart valves.
Artivion, Inc. (NYSE: AORT), a company specializing in cardiac and vascular solutions for aortic disease, will present at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 1:30 p.m. ET. The presentation will be available through a live webcast on Artivion's website, with an archived version accessible for 90 days post-event. Artivion offers diverse products including aortic stent grafts and On-X mechanical heart valves, serving over 100 countries globally.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
What is the primary focus of Artivion, Inc.?
Which product categories does Artivion offer?
How does Artivion support surgical procedures?
What role do clinical trials play in Artivion's strategy?
In which markets does Artivion operate?
How does Artivion differentiate itself from competitors?
What are some key benefits of using Artivion’s devices?
How is Artivion enhancing its product development?
